Literature DB >> 1775947

5-Hydroxytryptamine and 5-hydroxytryptamine-3 receptor antagonists.

M J Farthing1.   

Abstract

5-Hydroxytryptamine (5-HT) is present throughout the gastrointestinal tract, which acts as the major reservoir of this substance in the body. Its physiologic role has not been clearly established, although it seems likely that 5-HT is involved in the regulation of aspects of intestinal motility such as peristalsis and the migrating motor complex. In disease states the contribution of 5-HT is perhaps more clearly established, particularly its role in chemotherapy-induced emesis, in the carcinoid syndrome, and, possibly, in mediating the effect of some intestinal secretagogues, notably cholera toxin. Many of the functions of 5-HT in the gut have been elucidated as a result of the development of antagonists to 5-HT receptors. However, some of these compounds have 5-HT agonist activity as well as 5-HT receptor blocking activity, making interpretation of their effects in health and disease difficult. Nevertheless, 5-HT receptor antagonists are finding an important place in the management of the carcinoid syndrome and in chemotherapy-induced emesis and may well evolve as important agents for modulating gut motility and for inhibiting secretory states in the small and large intestine. The suggestion that 5-HT3 receptor antagonists might also modulate visceral sensation in the gut is of great interest because of their potential to relieve symptoms of functional bowel disorders such as pain, urgency, and bowel frequency.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1775947     DOI: 10.3109/00365529109111236

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  8 in total

Review 1.  Travellers' diarrhoea.

Authors:  M J Farthing
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

2.  Serotonin metabolism following platinum-based chemotherapy combined with the serotonin type-3 antagonist tropisetron.

Authors:  C P Schröder; W T van der Graaf; I P Kema; A Groenewegen; D T Sleijfer; E G de Vries
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist.

Authors:  M Miura; D C Lawson; E M Clary; A W Mangel; T N Pappas
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

4.  Characterization of the 5-hydroxytryptamine receptor type involved in inhibition of spontaneous activity of human isolated colonic circular muscle.

Authors:  F S Tam; K Hillier; K T Bunce
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

Review 5.  New drugs in the management of the irritable bowel syndrome.

Authors:  M J Farthing
Journal:  Drugs       Date:  1998-07       Impact factor: 9.546

6.  Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy.

Authors:  Liesbeth M Veenendaal; Inne H M Borel Rinkes; Cornelis J M Lips; Richard van Hillegersberg
Journal:  World J Surg Oncol       Date:  2006-06-26       Impact factor: 2.754

7.  Effects of ramosetron on gastrointestinal transit of Guinea pig.

Authors:  Yoo Mi Park; Young Ju Lee; Young Ho Lee; Tae Il Kim; Hyojin Park
Journal:  J Neurogastroenterol Motil       Date:  2013-01-08       Impact factor: 4.924

8.  Comparison of 24-h and overnight samples of urinary 5-hydroxyindoleacetic acid in patients with intestinal neuroendocrine tumors.

Authors:  Merete Gedde-Dahl; Espen Thiis-Evensen; Andreas Myklebust Tjølsen; Kjerstin Skrede Mordal; Morten Vatn; Deidi S Bergestuen
Journal:  Endocr Connect       Date:  2013-01-25       Impact factor: 3.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.